PMC:7417114 / 52139-52809 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T262","span":{"begin":160,"end":166},"obj":"Body_part"},{"id":"T263","span":{"begin":238,"end":244},"obj":"Body_part"},{"id":"T264","span":{"begin":282,"end":288},"obj":"Body_part"},{"id":"T265","span":{"begin":289,"end":296},"obj":"Body_part"},{"id":"T266","span":{"begin":563,"end":567},"obj":"Body_part"}],"attributes":[{"id":"A262","pred":"fma_id","subj":"T262","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A263","pred":"fma_id","subj":"T263","obj":"http://purl.org/sig/ont/fma/fma9637"},{"id":"A264","pred":"fma_id","subj":"T264","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A265","pred":"fma_id","subj":"T265","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A266","pred":"fma_id","subj":"T266","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"Sorafenib (Nexavar)\n(Bayer and Onyx Pharmaceuticals) High fat meal decreases bioavailability by 29%;\nmean relative bioavailability=38-49% for tablet form;\npeak plasma levels achieved 3 h after dosing;\nVd= 213 L (suggests potentially high tissue distribution despite a high level of plasma protein binding, likely due to high lipophilicity) (227) Metabolized mainly by hepatic CYP3A4; glucuronidation mediated by UGT1A9 400 mg (2x200 mg tablets) orally twice daily;\n99.5% binding (AAG, HSA) There have been several reported cases of sorafenib-induced interstitial lung disease (203); pulmonary toxicity in association with sorafenib has been reported to be uncommon (228)"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T79","span":{"begin":238,"end":244},"obj":"Body_part"},{"id":"T80","span":{"begin":563,"end":567},"obj":"Body_part"}],"attributes":[{"id":"A79","pred":"uberon_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/UBERON_0000479"},{"id":"A80","pred":"uberon_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Sorafenib (Nexavar)\n(Bayer and Onyx Pharmaceuticals) High fat meal decreases bioavailability by 29%;\nmean relative bioavailability=38-49% for tablet form;\npeak plasma levels achieved 3 h after dosing;\nVd= 213 L (suggests potentially high tissue distribution despite a high level of plasma protein binding, likely due to high lipophilicity) (227) Metabolized mainly by hepatic CYP3A4; glucuronidation mediated by UGT1A9 400 mg (2x200 mg tablets) orally twice daily;\n99.5% binding (AAG, HSA) There have been several reported cases of sorafenib-induced interstitial lung disease (203); pulmonary toxicity in association with sorafenib has been reported to be uncommon (228)"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T505","span":{"begin":485,"end":488},"obj":"Disease"},{"id":"T506","span":{"begin":550,"end":575},"obj":"Disease"},{"id":"T507","span":{"begin":563,"end":575},"obj":"Disease"}],"attributes":[{"id":"A505","pred":"mondo_id","subj":"T505","obj":"http://purl.obolibrary.org/obo/MONDO_0011848"},{"id":"A506","pred":"mondo_id","subj":"T506","obj":"http://purl.obolibrary.org/obo/MONDO_0015925"},{"id":"A507","pred":"mondo_id","subj":"T507","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"}],"text":"Sorafenib (Nexavar)\n(Bayer and Onyx Pharmaceuticals) High fat meal decreases bioavailability by 29%;\nmean relative bioavailability=38-49% for tablet form;\npeak plasma levels achieved 3 h after dosing;\nVd= 213 L (suggests potentially high tissue distribution despite a high level of plasma protein binding, likely due to high lipophilicity) (227) Metabolized mainly by hepatic CYP3A4; glucuronidation mediated by UGT1A9 400 mg (2x200 mg tablets) orally twice daily;\n99.5% binding (AAG, HSA) There have been several reported cases of sorafenib-induced interstitial lung disease (203); pulmonary toxicity in association with sorafenib has been reported to be uncommon (228)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T597","span":{"begin":58,"end":61},"obj":"http://purl.obolibrary.org/obo/UBERON_0001013"},{"id":"T598","span":{"begin":160,"end":166},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T599","span":{"begin":266,"end":267},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T600","span":{"begin":282,"end":288},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T601","span":{"begin":485,"end":488},"obj":"http://purl.obolibrary.org/obo/PR_000001932"},{"id":"T602","span":{"begin":563,"end":567},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T603","span":{"begin":563,"end":567},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T604","span":{"begin":577,"end":580},"obj":"http://purl.obolibrary.org/obo/CLO_0001180"},{"id":"T605","span":{"begin":632,"end":635},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"Sorafenib (Nexavar)\n(Bayer and Onyx Pharmaceuticals) High fat meal decreases bioavailability by 29%;\nmean relative bioavailability=38-49% for tablet form;\npeak plasma levels achieved 3 h after dosing;\nVd= 213 L (suggests potentially high tissue distribution despite a high level of plasma protein binding, likely due to high lipophilicity) (227) Metabolized mainly by hepatic CYP3A4; glucuronidation mediated by UGT1A9 400 mg (2x200 mg tablets) orally twice daily;\n99.5% binding (AAG, HSA) There have been several reported cases of sorafenib-induced interstitial lung disease (203); pulmonary toxicity in association with sorafenib has been reported to be uncommon (228)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T50571","span":{"begin":11,"end":18},"obj":"Chemical"},{"id":"T37004","span":{"begin":289,"end":296},"obj":"Chemical"},{"id":"T54174","span":{"begin":480,"end":483},"obj":"Chemical"},{"id":"T30134","span":{"begin":532,"end":541},"obj":"Chemical"},{"id":"T16018","span":{"begin":622,"end":631},"obj":"Chemical"}],"attributes":[{"id":"A1136","pred":"chebi_id","subj":"T50571","obj":"http://purl.obolibrary.org/obo/CHEBI_50928"},{"id":"A68514","pred":"chebi_id","subj":"T37004","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A77397","pred":"chebi_id","subj":"T54174","obj":"http://purl.obolibrary.org/obo/CHEBI_73318"},{"id":"A17077","pred":"chebi_id","subj":"T30134","obj":"http://purl.obolibrary.org/obo/CHEBI_50924"},{"id":"A35247","pred":"chebi_id","subj":"T16018","obj":"http://purl.obolibrary.org/obo/CHEBI_50924"}],"text":"Sorafenib (Nexavar)\n(Bayer and Onyx Pharmaceuticals) High fat meal decreases bioavailability by 29%;\nmean relative bioavailability=38-49% for tablet form;\npeak plasma levels achieved 3 h after dosing;\nVd= 213 L (suggests potentially high tissue distribution despite a high level of plasma protein binding, likely due to high lipophilicity) (227) Metabolized mainly by hepatic CYP3A4; glucuronidation mediated by UGT1A9 400 mg (2x200 mg tablets) orally twice daily;\n99.5% binding (AAG, HSA) There have been several reported cases of sorafenib-induced interstitial lung disease (203); pulmonary toxicity in association with sorafenib has been reported to be uncommon (228)"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1509","span":{"begin":376,"end":382},"obj":"Gene"},{"id":"1510","span":{"begin":412,"end":418},"obj":"Gene"}],"attributes":[{"id":"A1509","pred":"tao:has_database_id","subj":"1509","obj":"Gene:1576"},{"id":"A1510","pred":"tao:has_database_id","subj":"1510","obj":"Gene:54600"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Sorafenib (Nexavar)\n(Bayer and Onyx Pharmaceuticals) High fat meal decreases bioavailability by 29%;\nmean relative bioavailability=38-49% for tablet form;\npeak plasma levels achieved 3 h after dosing;\nVd= 213 L (suggests potentially high tissue distribution despite a high level of plasma protein binding, likely due to high lipophilicity) (227) Metabolized mainly by hepatic CYP3A4; glucuronidation mediated by UGT1A9 400 mg (2x200 mg tablets) orally twice daily;\n99.5% binding (AAG, HSA) There have been several reported cases of sorafenib-induced interstitial lung disease (203); pulmonary toxicity in association with sorafenib has been reported to be uncommon (228)"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T147","span":{"begin":550,"end":575},"obj":"Phenotype"}],"attributes":[{"id":"A147","pred":"hp_id","subj":"T147","obj":"http://purl.obolibrary.org/obo/HP_0006530"}],"text":"Sorafenib (Nexavar)\n(Bayer and Onyx Pharmaceuticals) High fat meal decreases bioavailability by 29%;\nmean relative bioavailability=38-49% for tablet form;\npeak plasma levels achieved 3 h after dosing;\nVd= 213 L (suggests potentially high tissue distribution despite a high level of plasma protein binding, likely due to high lipophilicity) (227) Metabolized mainly by hepatic CYP3A4; glucuronidation mediated by UGT1A9 400 mg (2x200 mg tablets) orally twice daily;\n99.5% binding (AAG, HSA) There have been several reported cases of sorafenib-induced interstitial lung disease (203); pulmonary toxicity in association with sorafenib has been reported to be uncommon (228)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T424","span":{"begin":0,"end":19},"obj":"Sentence"},{"id":"T425","span":{"begin":20,"end":100},"obj":"Sentence"},{"id":"T426","span":{"begin":101,"end":154},"obj":"Sentence"},{"id":"T427","span":{"begin":155,"end":200},"obj":"Sentence"},{"id":"T428","span":{"begin":201,"end":464},"obj":"Sentence"},{"id":"T429","span":{"begin":465,"end":670},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Sorafenib (Nexavar)\n(Bayer and Onyx Pharmaceuticals) High fat meal decreases bioavailability by 29%;\nmean relative bioavailability=38-49% for tablet form;\npeak plasma levels achieved 3 h after dosing;\nVd= 213 L (suggests potentially high tissue distribution despite a high level of plasma protein binding, likely due to high lipophilicity) (227) Metabolized mainly by hepatic CYP3A4; glucuronidation mediated by UGT1A9 400 mg (2x200 mg tablets) orally twice daily;\n99.5% binding (AAG, HSA) There have been several reported cases of sorafenib-induced interstitial lung disease (203); pulmonary toxicity in association with sorafenib has been reported to be uncommon (228)"}

{"project":"2_test","denotations":[{"id":"32778962-21392074-84130740","span":{"begin":341,"end":344},"obj":"21392074"},{"id":"32778962-20702754-84130741","span":{"begin":577,"end":580},"obj":"20702754"},{"id":"32778962-22752255-84130742","span":{"begin":666,"end":669},"obj":"22752255"}],"text":"Sorafenib (Nexavar)\n(Bayer and Onyx Pharmaceuticals) High fat meal decreases bioavailability by 29%;\nmean relative bioavailability=38-49% for tablet form;\npeak plasma levels achieved 3 h after dosing;\nVd= 213 L (suggests potentially high tissue distribution despite a high level of plasma protein binding, likely due to high lipophilicity) (227) Metabolized mainly by hepatic CYP3A4; glucuronidation mediated by UGT1A9 400 mg (2x200 mg tablets) orally twice daily;\n99.5% binding (AAG, HSA) There have been several reported cases of sorafenib-induced interstitial lung disease (203); pulmonary toxicity in association with sorafenib has been reported to be uncommon (228)"}